Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405541 | 1.00 | TRPM8 (0.45) | TRPM8NFE2L2DYRK1ACLK4ROCK1 | |
| SCHEMBL14405625 | 0.85 | TRPM8 (0.53) | TRPM8NFE2L2CLK4 | |
| SCHEMBL15023734 | 0.85 | TRPM8 (0.53) | TRPM8NFE2L2CLK4 | |
| Hydrochloric Acid SCHEMBL15021305 | 0.84 | TRPM8 (0.52) | TRPM8NFE2L2CLK4 | |
| Hydrochloric Acid SCHEMBL15021302 | 0.84 | TRPM8 (0.52) | TRPM8NFE2L2CLK4 | |
| SCHEMBL15021812 | 0.83 | TRPM8 (0.53) | TRPM8ROCK1 | |
| SCHEMBL14405534 | 0.83 | TRPM8 (0.53) | TRPM8ROCK1 | |
| SCHEMBL15021334 | 0.81 | TRPM8 (0.42) | TRPM8 | |
| SCHEMBL14405578 | 0.81 | TRPM8 (0.53) | TRPM8KCNA5L3MBTL1 | |
| SCHEMBL15022557 | 0.81 | TRPM8 (0.53) | TRPM8KCNA5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885NFE2L2 3338/4885DYRK1A 3477/4885 |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885NFE2L2 3338/4885DYRK1A 3477/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885NFE2L2 3338/4885DYRK1A 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.